{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043393","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.131663+00:00","generated_at":"2026-06-07T19:26:26.649921+00:00","sec_items":["1.02","5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AgeX Therapeutics COO to depart as Juvenescence terminates services agreement; $3.9M debt","bullets":["Juvenescence notified AgeX it is terminating the agreement that provided Nafees Malik as COO; termination effective Dec 31, 2023.","Dr. Malik's engagement as COO of AgeX and its subsidiary Reverse Bioengineering ends December 27, 2023.","As of Nov 27, 2023, AgeX owed Juvenescence $3.9 million in secured loans and fees.","Juvenescence, AgeX's largest shareholder (79.4% of outstanding common shares), provided Dr. Malik's services at 85% cost.","No replacement for COO has been announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043393","json":"https://secwatch.observer/filing/0001493152-23-043393.json","markdown":"https://secwatch.observer/filing/0001493152-23-043393.md","text":"https://secwatch.observer/filing/0001493152-23-043393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:26:26.649921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f22667abb","claim":"Nafees Malik departed as Chief Operating Officer at Serina Therapeutics, Inc..","evidence_excerpt":"In connection with the termination of the agreement pursuant to which Juvenescence has provided the services of our Chief Operating Officer, Nafees Malik, as set forth in","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"f4ee36c39e10405a26478a9f8457d653e1d50faf","claim":"Serina Therapeutics, Inc. terminated Service Agreement with Juvenescence Limited for Dr. Nafees Malik with Juvenescence Limited valued at Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa (effective 2023-12-31).","evidence_excerpt":"On November 27, 2023, Juvenescence Limited (“Juvenescence”) notified AgeX that Juvenescence is terminating a March 29, 20219 the agreement that incorporated arrangements in effect since October 18, 2018 pursuant to which Juvenescence has provided AgeX with the services of Juvenescence’s employee Nafees Malik who served as Chief Operating Officer of AgeX and our subsidiary Reverse Bioengineering, Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Value","value":"Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa"},{"label":"Effective","value":"2023-12-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}